Velphoro: payments to doctors
Payments that named Velphoro as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.3M
- Providers
- 7,030
- Transactions
- 50,891
- Average per transaction
- $64
The per-transaction average — $64 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,030 providers the average total is $466, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Fresenius USA Marketing, Inc. | $3,251,550 | 99.3% |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | $12,972 | 0.4% |
| Vifor (international) Ltd. | $4,856 | 0.1% |
| Fresenius USA Manufacturing, Inc. | $3,765 | 0.1% |